Articles from TheracosBio

TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, is available to customers at Publix Super Markets (Publix) pharmacies. Publix, the largest employee-owned company in the country, has over 1,400 locations throughout the Southeast United States.

A new study published in JAMA Network Open titled “Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes” underscores the need for addressing disparities in care and improving access to important therapies for type 2 diabetes. This study further underscores recent data compiled by the American Diabetes Association which states that diabetes is the most expensive chronic condition in the United States, and millions of Americans struggle to afford effective treatment of their type 2 diabetes and associated complications. Seeking to address this critical health issue, BRENZAVVY® (bexagliflozin) is a safe, effective and affordable option for adults with type 2 diabetes.

TheracosBio today announced that it is a sponsor of the upcoming, first annual Achieving Diabetes Equity in Practice Today (ADEPT) Conference taking place at the Chicago Marriott Downtown on November 12th and 13th. The Conference, the result of a collaborative effort by the American Diabetes Association and the T1D Exchange, will bring together key stakeholders focused on achieving health equity in type 1 and type 2 diabetes.

TheracosBio and BAMCO Africa, Inc. today announced they have partnered to bring BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, to patients in Sub-Saharan Africa. BAMCO is a pioneering healthcare company committed to providing access to innovative therapies for patients in Sub-Saharan Africa. BAMCO was carefully selected by TheracosBio due to the two companies’ shared mission and BAMCO’s strong leadership team and depth of experience in the region.

TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, is available to PBA Health members. PBA Health is a member-governed market leader in supply chain pharmacy solutions for over 2,500 independent community pharmacies and stocks more than 3,000 products. PBA Health is one of TheracosBio’s carefully selected pharmaceutical suppliers that carry and distribute BRENZAVVY in the United States.

TheracosBio today announced that, in the wake of the federal government release of negotiated prices under the Medicare Drug Price Negotiation Program, BRENZAVVY® (bexagliflozin) remains the lowest priced sodium-glucose cotransporter 2 (SGLT2) as compared to the Negotiated Monthly List Price, also referred to as the Maximum Fair Price, for other drugs in the SGLT2 class.

TheracosBio today announced the publication of a study titled “Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: a 24-week, randomized, double-blind, active-controlled, phase 3 trial” in Journal of Diabetes. The study results demonstrated the noninferiority of BRENZAVVY® (bexagliflozin) to dapagliflozin, marketed as Farxiga in the United States, in patients with type 2 diabetes mellitus.

TheracosBio today announced that it is extending its collaboration with the Mark Cuban Cost Plus Drug Company. Under the partnership, BRENZAVVY® (bexagliflozin) is available directly to healthcare businesses under the Cost Plus Drugs Marketplace program.

TheracosBio today announced the publication of a meta-analysis that confirms the cardiovascular safety profile of BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, will be available to Independent Pharmacy Cooperative (IPC) members. IPC is the nation's largest group purchasing organization owned by independent pharmacy, serving more than 7,000 pharmacies and stocking more than 4,000 products. IPC will be the first pharmaceutical wholesaler to carry and distribute BRENZAVVY in the United States.

TheracosBio today announced that its consolidated group of companies has signed a royalty financing agreement with HealthCare Royalty (HCRx). Under the terms of the agreement, HCRx will be entitled to a portion of the future royalties and milestone payments from the commercialization of a veterinary product developed by TheracosBio and commercialized by Elanco Animal Health. In exchange, the TheracosBio group received an upfront cash payment.

TheracosBio and SmithRx, a next-generation pharmacy benefits management (PBM) company, today announced that SmithRx will offer access to BRENZAVVY™ (bexagliflozin), TheracosBio’s FDA-approved oral medication for adults with type 2 diabetes, through its partnership with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs). Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.

TheracosBio today announced the publication of a study titled “Bexagliflozin as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults: a 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial” in Diabetes, Obesity and Metabolism. The Phase 3 study assessed the safety and effectiveness of Brenzavvy™ (bexagliflozin), 20 mg, in adults with type 2 diabetes mellitus as an adjunct to metformin, as compared to placebo. The study results showed that BRENZAVVY treatment improved glycemic control and decreased systolic blood pressure levels and fasting plasma glucose levels in patients with type 2 diabetes.

TheracosBio today announced the appointment of Brian Connelly as President and Chief Executive Officer. Brian brings to the position more than two decades of biopharmaceutical industry experience bridging business and law. He succeeds Albert R. Collinson, Ph.D., who is stepping down as CEO after leading the company from phase 1 clinical studies to an FDA approval and commercial launch of Brenzavvy™ (bexagliflozin).

TheracosBio today announced that Brenzavvy™ (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, is now available by prescription through the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs). A 30-day supply is available from Cost Plus Drugs for $47.85 plus shipping and handling.

TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes.

TheracosBio today announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy™ (bexagliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. BRENZAVVY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. BRENZAVVY is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. BRENZAVVY is contraindicated in patients who are hypersensitive to bexagliflozin or any tablet ingredient and is not indicated for the treatment of type 2 diabetes in patients with end stage renal disease or who are receiving dialysis.